HLA-mismatched allogeneic hematopoietic stem cell transplantation for high-risk advanced hematological disease with the adjustments of immunosuppressants and low-dose alemtuzumab.
- Conditions
- High-risk advanced hematological disease(leukemia and malignant lymphoma in non-remission, MDS with more than 20% of blast, and relapsed disease after allogeneic transplantation)
- Registration Number
- JPRN-UMIN000018298
- Lead Sponsor
- Division of Hematology, Saitama Medical Center, Jichi Medical University
- Brief Summary
The rate of the achievement of primary outcome measure was more than 80%, but the RR at 1 year was high. Most patients had uncontrollable, non-remission disease, and in addition, many patients had a history of previous allogeneic transplantation. These affected outcomes a lot, but we need to decrease a relapse rate by inducing new methods, such as the further reduction of immunosuppressants after transplantation and donor lymphocyte infusion (DLI) at the early phase after transplantation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 27
Not provided
1.Patients with poorly controlled active infection. 2.Patients with coexistence of malignancy. 3.Patients who are pregnant or nursing. 4.Patients with serious mental disorder. 5.Patients with HIV antibody positive. 6.Patients who are allergic to drugs used in conditioning regimen or GVHD prophylaxis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method